Aided by the Orphan Drug Act of 1983, biotech and pharma companies have sought
development treatments for the approximately 7,000 rare diseases that have been identified.
In order to successfully commercialize a
rare disease product, manufacturers must
consider the needs of multiple stakeholders.
McKesson Corporation, a global leader in healthcare supply chain management
solutions, announced today that it has completed the previously announced acquisition of
McKesson Corporation today announced that
it has signed a definitive agreement to purchase RxCrossroads, a provider of tailored services
to pharmaceutical and biotechnology manufacturers, from CVS Health Corporation.
RxCrossroads' third quarter legislative brief of 2017 is now available. Learn more about recent reimbursement and coverage policy updates.
RxCrossroads' second quarter legislative brief of 2017 is now available. Learn more about recent reimbursement and coverage policy updates.